Pearl River Holdings Limited (PRH) News

Form 8-K - Current report

Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia

Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill an...

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Form 8-K - Current report

Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering

CHATHAM, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix”...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering

CHATHAM, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix”...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Tonix Pharmaceuticals Announces Proposed Public Offering

CHATHAM, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix”...

Form 8-K - Current report

Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia

Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia...

Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program

CHATHAM, N.J., July 01, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or...

Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering

CHATHAM, N.J., June 28, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix”...